biontech BioNTech Acquires AI Firm InstaDeep for $440M to Boost Drug Discovery BioNTech purchases InstaDeep in a deal worth up to £562 million to integrate artificial intelligence across its immunotherapy platforms. The acquisition brings 240 AI and machine learning experts into BioNTech's workforce.
biontech BioNTech Buys AI Startup InstaDeep for $680 Million to Boost Cancer Drug Discovery BioNTech acquires U.K.-based AI startup InstaDeep in a deal worth up to $680 million to advance its personalized cancer treatments. The purchase builds on a previous partnership between the two companies.
pfizer Pfizer and BioNTech Request Emergency FDA Authorization for 95% Effective COVID-19 Vaccine Pfizer and BioNTech officially request emergency use authorization from the FDA for their highly effective COVID-19 vaccine. The companies plan to distribute millions of doses globally within hours of receiving approval.
pfizer Pfizer and BioNTech Submit Covid-19 Vaccine for FDA Emergency Authorization Pfizer and BioNTech officially ask the FDA to grant emergency use authorization for their coronavirus vaccine. The request brings the world one step closer to deploying a highly effective shot.
pfizer Pfizer Seeks Emergency FDA Approval for Highly Effective COVID-19 Vaccine Pfizer and BioNTech officially request emergency use authorization from the FDA for their COVID-19 vaccine after clinical trials show 95% effectiveness. The company states it is ready to begin distributing the vaccine within hours of receiving federal approval.
pfizer Pfizer Seeks Emergency FDA Approval for Highly Effective COVID-19 Vaccine Pfizer and BioNTech officially apply for FDA emergency use authorization for their coronavirus vaccine, which shows 95% efficacy in final trials. If approved, the first doses could reach high-risk Americans by mid-December.
pfizer Pfizer Covid-19 Vaccine Shows Over 90% Effectiveness in Clinical Trials Pfizer and BioNTech report their coronavirus vaccine is more than 90% effective at preventing infection, far exceeding initial expert expectations. The breakthrough sparks a massive global market rally and offers renewed hope for ending the pandemic.
pfizer Pfizer and BioNTech Report 90 Percent Efficacy for Experimental COVID-19 Vaccine Pfizer and BioNTech announce that their experimental coronavirus vaccine shows more than 90 percent effectiveness in preventing COVID-19 during a large phase III trial. The genetically engineered vaccine uses an innovative RNA approach that allows for rapid manufacturing.